You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205041 - 205050 of 207728 results
  1. Cell Culture Production of Marine-Derived Bioactive Terpenses

    SBC: NAUTILUS BIOSCIENCES, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The marine environment has proven to be a prolific source of novel bioactive molecules with great potential in a number of therapeutic areas. Currently, marine natural products are in clinical trials for cancer, analgesia, allergy and cognitive diseases. It is clear that research groups will continue to identify new marine natural products which offer great po ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. High-Energy Imaging in Support of Radionuclide Therapy

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to design and build cameras that can efficiently detect and image isotopes that have gamma rays with energies that are typically beyond those effectively accessible with conventional cameras. There are no nuclear medicine clinical cameras, today, that combine high efficiency with the ability to image high-energy gamma ra ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Automated, Web Based Software Development for Predictive QSAR Modeling

    SBC: PHORCAST, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): In the course of previous basic studies in our laboratory, we have developed statistically significant and robust Quantitative Structure-Activity Relationships (QSAR) methodologies, which incorporate rigorous validation procedures and lead to models with a high predictive power and practical utility. The methodologies are built upon the similarity principle, i. ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Lipid/DNA/Antigen Complexes for Influenza A Viral Vaccination

    SBC: JUVARIS BIOTHERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Influenza A (fluA) infection causes annual substantial morbidity and mortality worldwide, particularly for infants, the elderly, and the immuncompromised. FluA mainly replicates in the respiratory tract, with virulent strains also disseminating to other tissues, such as the central nervous system. A growing concern is the recent spread of virulent avian influen ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Recombinant system for ultra-large scale biomanufacturing of therapeutic proteins

    SBC: SOLAZYME, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Solazyme, Inc. in collaboration with the City University of New York (CUNY) proposes to develop a novel recombinant protein expression platform by transforming the photosynthetic microalgal species Dunaliella salina. The organism's autotrophic production of nutrients from sunlight and extreme halotolerance will allow new biomanufacturing processes to overcome t ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

    SBC: ElSohly Laboratories, Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): The long term objectives of this proposal are aimed at the development of new composition(s) to be used for the prophylactic treatment/prevention of poison ivy contact dermatitis in sensitive individuals. Poison ivy/poison oak and another related species poison sumac are the main cause of occupational hazards for outdoor workers in the United States. Most of th ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Tai Chi Training for People with Parkinson's Disease

    SBC: DESCHUTES RESEARCH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): People with Parkinson's disease (PD) are faced with many difficulties, including muscle stiffness, tremors, slowness and poverty of movement, difficulty with balance, difficulty walking, speech problems, and loss of voice. Certain types of physical activity such as walking, swimming, or gardening, are considered important for people with PD in terms of maintain ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Oncolytic Viral Delivery of Oncogene siRNA

    SBC: GRADALIS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Oncolytic viruses represent an emerging group of novel cancer therapeutics that targets cancer cells with defined genetic defects (p53, Rb). Oncolytic viruses eliminate cancer cells through manifestations of cytopathic effects and the viral replication process. Since the same virus does not survive in normal cells, minimal toxicity is produced. Phase I and II c ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Oral Formulation of Zonulin Antagonist AT-1001 for Diabe

    SBC: ALBA THERAPEUTICS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The trigger for autoimmune destruction of pancreatic beta cells in Type 1 diabetes (T1D) is unclear. Evidence exists for the role of increased intestinal permeability, secondary to intestinal tight junctions (tj) disassembly, in the pathogenesis of various autoimmune diseases including T1 D. Over the last decade our studies have focused on the mechanism(s) of a ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. New Opioids for Alcoholism

    SBC: BEHAVIORAL PHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Highly potent, orally active, metabolically stable, long-lived opioid agents for the treatment of alcoholism that have decreased side effects such as nausea, addiction liability, immunosuppression and respiratory depression represents a great unmet need. While a mu opioid receptor antagonist is currently approved by the FDA for alcoholism, it possesses several ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government